Price movement over the last 24 hours
Abeona Therapeutics Inc vs Select Medical Holdings Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Select Medical Holdings Corporation is far larger — about 5.5× Abeona Therapeutics Inc's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SEM | |
|---|---|---|
Market Cap | $373.32M | $2.05B |
Sector | Health | Health |
52-Week High | $7.23 | $16.66 |
52-Week Low | $4.17 | $11.77 |
Enterprise Value | $228.22M | $5.01B |
Dividend Yield | — | 1.51% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, with a bullish technical signal supported by oversold RSI readings. The company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43 and P/S of 0.36 indicating reasonable valuation. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share, finalized on June 30, 2026.
The acquisition at $16.50 per share, just below the current price, limits near-term upside, while ongoing legal investigations into the board's fiduciary duties pose governance risks. Analyst consensus is mixed with 35.71% buy ratings, but stagnant revenue and declining net income margins signal fundamental challenges. Investors should weigh the acquisition's finality against operational headwinds and shareholder litigation risks.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →